Purpose: The aim of the present work was to develop solid lipid microparticles (SLMs), as dry powders containing quercetin for direct administration to the lung. Methods: Quercetin microparticles were prepared by o/w emulsification via a phase inversion technique, using tristearin as the lipid component and phos phatidylcholine as an emulsifier. The quercetin SLMs were characterised for morphology, drug loading (15.5% ± 0.6, which corresponded to an encapsulation efficiency of 71.4%), particle size distribution, response to humidity, crystallinity, thermal behaviour and in vitro respirable fraction. Furthermore, the toxicity and the in vitro transport of the SLMs on an air liquid interface model of the Calu-3 cell line were also investigated using a modified twin-stage impinger apparatus. Results: Results showed that quercetin SLMs could be formulated as dry powder suitable for inhalation drug delivery (20.5 ± 3.3% fine particle fraction 64.46 lm) that was absorbed, via a linear kinetic model across the Calu-3 monolayer (22.32 ± 1.51% over 4 h). In add ition, que rcetin SLMs were shown to be nontoxic at the concentrations investigated. Interestingly, no apical to basolateral transport of the micronised quercetin was observed over the period of study. Conclusions: These observations suggest quercetin diffusion was enhanced by the presence of the lipid/ emulsifying excipients in the SLMs; however further studies are necessary to elucidate the exact mechanisms.
Introductio n
Quercetin is a flavonoid, a natural substance with a phenolic structure. Flavonoids can be divided into various classes on the basis of their molecula r structure with quercetin belonging to the flavone class, which has a planar structure due to the double bond in the central ring of the 2-phenylchr omen-4-one (2-phenyl-1-benzopyran-4-one) backbone. This flavonoid group can be found in abundance in onions, apples, broccoli, and berries (Nijveldt et al., 2001; Formica and Regelson , 1995 ) . Quercetin pharmacokine tics and bioavailability in humans has previousl y been studied Graefe et al., 2001 ) . An important effect of quercetin is its ability to scavenge for oxygen-der ived free radicals (Heijnen et al., 2001 ) , given its antioxidant properties at low concentrations (Robaszkiew icz et al., 2007 ) . Furthermor e, in vitro and in vivo experiments have also shown that flavonoids possess potential anti-inflammatory, anti-allergic , antiviral, anti-carcinogeni c and anti-asthma tic propertie s (Pettinari et al., 2006; Wu et al., 2004; Li et al., 2001; Davis et al., 2008; Gang et al., 2012; .
Specifically, for the lungs, cell culture studies have shown that quercetin can reduce infectivity of target cells and replication against a wide variety of respiratory viruses, including herpes simplex virus and adenovirus (Chiang et al., 2003 ) , coronavirus (Debiaggi et al., 1990 ) , parainfluenza and respiratory syncytial virus (Kaul et al., 1985 ) , rhinovirus (Dimova et al., 2003 ) , and severe acute respirato ry syndrome (Chen et al., 2006 ) . Furthermor e, there is evidence that quercetin plays a critical role in the amelioration of the pathogenic process of asthma in a murine model (mice) (Park et al., 2009 ), due to the alteration of specific cytokine production (Th1/Th2) and transcriptor factors (T-bet and GATA-3) gene expression in OVA-induced asthma model mice, suggesting quercetin could be used as a new therapeutic approach to allergic airway diseases. More recently, when given orally to guinea pigs, quercetin has been found to reduce hyper-reacti vity of airways, one of the main attributes of allergic asthma (Joskova et al., 2011) ; causing significant broncodilation . Furthermore, a report suggests that flavonoids such as quercetin and luteolin could stimulate Cl À secretion by activating an entry step of Cl À across the basolater al membrane through Na + /K + /2Cl À co-transpor ter; contributing to maintenanc e and/or production of airway surface liquid by regulatin g Cl À secretion in airway epithelial cells (Asano et al., 2009 ) , very important in chronic obstructi ve pulmonary disease.
Quercetin is sparingly soluble in water and has poor bioavailability. As a result, the clinical applicati on of the drug is greatly restricted. Previous studies have tried to resolve this issue by producing nanocrystals with enhanced dissolution (Kakran et al., 2012; Li et al., 2009 ). An alternative approach would be to incorporate the drug into a lipid matrix (Li et al., 2009 ) . The production of solid lipid micropartic les (SLMs) has been previously studied as a respiratory drug delivery vehicle for both poorly water-soluble drugs, such as budesonide ) and for more water-solub le drugs, such as salbutamol (Scalia et al., 2012 ) . There are many advantages in using SLMs (Jaspart et al., 2005 ) , with the most significant being the ability to control release after deposition. Furthermore, SLMs should be well tolerated in vivo since they are made of physiolog ical compounds . Of course, the toxicity of the surfactants and other excipients, used for their manufacture, needs to be considered.
While solid lipid nanoparticl es are currently attracting a lot of attention in the research communi ty, solid lipid micropatrtic les have been rather unexploited, especially for inhalation drug delivery Scalia et al., 2012; Jaspart et al., 2005 ) , where particles should have an optimum aerodynamic diameter between 1 and 6 lm (Patton, 1999 ) . Mezzena et al. (2009) and Scalia et al. (2012) used this concept to deliver budesonide and salbutamol, two anti-asthma drugs, respectively, using glycerol behenate as the solid lipid component. In other studies, Dellamary et al. (2004) , used dipalmitoyl phosphatidylch oline, a biocompatible lipid and component of normal lung surfactant, to modulate immunoglo bulin release while Sanna et al. (2004) applied the same concept for the formulat ion of SLMs to be used as carrier for lung delivery, using Compritol 888 as lipophilic component and Poloxamer as emulsifying agent.
The aim of this study was to investigate the potential use of solid lipid micropartic les containing quercetin delivered as a dry powder for inhalation. The physicochemi cal characteristics of this formulation was investigated together with aerosol performanc e, in vitro cell toxicity and transport studies, using a Calu-3 adenocarcinoma cell line grown using an air-interface model.
Materials and methods

Materials
Micronised quercetin hydrate (referred to as quercetin hereafter) and tristearin were supplied by Sigma Aldrich (Steinheim, Germany). Phosphatidylchol ine was supplied by Cargill (Hamburg, Germany). Ammonium acetate was supplied by Ajax Finechem Pty Ltd. (Sydney, Australia). Acetic acid was purchased from AnalaR VWR International (Poole, England) and EDTA di-sodium salt was supplied by APS Finechem (Sydney, Australia).
The Calu-3 cell line (HTB-55) was purchased from the American Type Cell Culture Collection (ATTC, Rockville, USA). Dulbecco's modified Eagle's medium, fetal bovine serum, Hanks balanced salt solution, phosphate buffer saline, HEPES, trypsin-EDTA solution (2.5 g/L trypsin, 0.5 g/L EDTA), L-glutamine solution (200 mM), nonessential amino acids solution and CelLytic M Cell Lysis (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholat e, 0.1% SDS) were supplied by Invitrogen (Sydney, Australia). Transwel l cell culture supports (0.33 cm 2 polyester, 0.4 lm pore size) were obtained from Corning Costar (Lowell, MA, USA).
All solvents were analytica l grade and were obtained from Sigma (Sydney, Australia).
Water was purified by Milli-Q reverse Osmosis (Molsheim, France).
Methods
Preparatio n of the solid lipid microparti cles
For the development of SLMs loaded with quercetin, melt o/w emulsification techniqu e was employed, since it circumvents the use of organic solvents Jaspart et al., 2005) . This approach is environmentall y friendly, but also eliminates the potential for residual solvent in the final dosage form. Quercetin (1 g) was dissolved into a melted (70-75°C) lipid phase (3.6 g tristearin) and the phase inversion was obtained adding hot (70-75°C) MilliQ water (50 mL), containing 0.7 g of phosphat idylcholine as surfactant. The mixture was maintained at 75°C and was subjected to high-shear mixing (21,500 rpm for 2 min, using a T-25 Ultra-Turrax; IKA-Wer k, Staufen, Germany). Addition ally, the o/w emulsion was sonicated at a constant duty cycle (22 kHz) for 2 min, using a probe (Microson XL2000 Ultrasonic Cell Disruptor, Misonix, Farmingd ale, NY) at a power input of 80 W. The emulsion was quickly cooled to a room temperature , using an ice bath and the formed micropartic les recovered by freeze-drying at À50°C (Hetosicc, Heto Lab Equipment, Saint-Julie, Canada).
The amount of quercetin entrapped in the SLMs was determined by heating (75°C for 2 min) and sonication (10 min) of the micropar ticles (20-25 mg) in ethanol in sealed glass vials. The obtained sample was diluted to volume (50 mL) with methano l, filtered and assayed by high performanc e liquid chromatograp hy (HPLC).
2.2.2.
Physical and chemical characterisati on 2.2.2.1. Particle size analysis. The particle size distribution of the SLMs was analysed using laser diffraction (Malvern Mastersizer 2000, Malvern Instruments Ltd., UK). Samples of powder (ca. 10 mg) were dispersed using the Scirocco dry dispersion unit (Malvern, UK) with a feed pressure of 4 Bar and feed rate of 50%. Samples were analysed in triplicate, with an obscurati on value between 0.3% and 10% and a reference refractive index of 1.553.
Scanning electron microscopy.
The morphology of SLMs particles was studied using a field emission scanning electron microscope (Zeiss Ultra plus, Carl Zeiss Pty Ltd., Sydney, Australia ). The samples were sputter coated with gold to a thickness of 15 nm, under an argon atmosph ere prior to analysis. Samples were dispersed onto carbon sticky tabs and images were taken at random locations .
2.2.2.3. Differential scanning calorimetry. The thermal response of quercetin raw material and SLM powders were studied using differential scanning calorimetry (DSC 823e; Mettler-Tol edo, Schwerzenbach, Switzerland ).
Samples (3-5 mg) were crimp-sealed in DSC sample pans and exposed to a 10°C min À1 temperature ramp between 40 and 400°C. Exothermal and endothermi c peak temperature s, onset temperat ure and heat of enthalpy (DH) for each peak were determined using STARe software V.9.0x (Mettler Toledo, Greifensee, Switzerla nd).
2.2.2.4. X-ray powder diffraction. The X-ray powder diffraction (XRPD) pattern for the SLMs was analysed using a D5000 X-ray powder diffractome ter (Siemens, Munich, Germany). Measurements were conducte d at 25°C, using Cu Ka radiation at 30 mA and 40 kV, with angular increment of 0.04 °s À1 .
2.2.2.5. Dynamic Vapour Sorption. Dynamic Vapour Sorption (DVS) was used to investiga te the relative moisture sorption and stability of the quercetin raw material and SLMs, with respect to humidity. Samples (ca. 15 mg) were added to glass sample pans, which were placed in the sample chamber of a DVS (DVS-1, Surface Measurement Systems Ltd., London, UK). Each sample was dried at 0% RH before being exposed to 10% RH increments for two 0-90% RH cycles (25°C). Equilibrium moisture content at each humidity step was determined by a dm/dt of 0.0005% min À1 .
HPLC method of quercetin quantification
Chemical analysis of quercetin was performed by High-Performance Liquid Chromatograp hy (HPLC) using a Shimadzu Prominence UFLC system equipped with an SPD-20 A UV-Vis detector, LC-20AT solvent delivery unit, SIL-20A HT autosampler (Shimadzu Corporation , Japan) and NovaPak C18 column (5 lm, 150 Â 3.9 mm, Waters, Ireland). The HPLC settings were as follow: detection wavelength 370 nm, flow rate 0.4 mL min À1 , injection volume 100 lL, and retention time of 4.5 min. The mobile phase was a mixture of acetate buffer and acetonitrile (55: 45, v/v) and 1 mM EDTA. Standard linearity was obtained between 0.2 and 20 lg mL À1 .
In vitro aerosol studies
The aerosolisation of quercetin SLMs were analysed using an Aerolizer Ò dry powder inhalation (DPI) device (Novartis, Surrey, UK) and a next generation impactor (NGI) (Copley Scientific, Nottingham, UK) according to the method specified for dry powder inhalers in the pharmacopoei a (British Pharmacop oeia, 2012 ). Briefly, prior to testing, all eight NGI collection cups were coated with silicon oil to eliminate particle bounce. 10 mg ± 0.1 mg of quercetin SLMs were weighed and filled in size 3 gelatine capsules (Capsugel, Sydney, Australia ) and placed in the Aerolizer Ò . A mouthpiece adaptor fitted into a United States Pharmacopei a (USP) throat was used to connect the Aerolizer Ò to the NGI. The particles were aerolised at 60 L min À1 for 4 s. The device containing the capsule, throat and the stages were then washed separately with methano l and the samples were analysed using HPLC. The mass balance was calculated as the recovery from the stage deposition, capsule and device. In addition, the fine particle dose (FPD) (drug recovered from stages 3 to filter) (64.46 lm) and the fine particle fraction (FPF) (FPD/Total dose Â 100) were calculated .
Cell viability assay after exposure to quercetin SLMs
The toxicity of quercetin SLMs was assessed by measuring the viability of Calu-3 cells in a liquid covered culture, following 3 days drug exposure to increasing drug concentratio ns, as previousl y described (Haghi et al., 2010 In addition, measureme nt of the transepithe lial electrical resistance (TEER) was performed using EVOM voltohmm eter (World Precision Instrument, USA) connected to STX-2 chopstick electrodes. 10 measure ments were taken per well after the experiment to confirm the maintenance of barrier integrity over 4 h of experiment. Subtracting the resistance of a cell-free insert and correcting the value for the surface area of the Transwell calculated the resistance.
2.2.6. In vitro drug diffusion/transp ort studies using air interface Calu-3 cell culture
The transport of quercetin from the SLMs was studied using a Calu-3 lung epithelial model. The culture condition s for the Calu-3 cell air interface model were as previously described (Haghi et al., 2010 ) . Briefly, Calu-3 cells were grown and subcultur ed in Dulbecco's Modified Eagle's medium (F-12 containing 10% (v/v) fetal calf serum, 1% (v/v) non essential amino acid solution and 1% (v/v) L-glutamine solution). Cells were then seeded on Transwel l polyester inserts at a density of 5 Â 10 5 cells cm À2 . After 24 h, medium was removed from the apical chamber and the basolater al medium replaced every alternate day with fresh medium to establish an air-interf ace model over 12-14 days. Prior to transport studies the viability and integrity of the cell monolayer with respect to quercetin SLMs was evaluated.
A modified in vitro aerosol testing apparatus (twin stage impinger TSI, Radleys, Essex, UK) that allows the attachment of a Transwell containing Calu-3 epithelial cells was used to study the mechanis m of drug deposition, dissolution and diffusion/transp ort (Haghi et al., 2010 (Haghi et al., , 2012 . Before the drug transport studies, the TSI flow rate was set to 60 L min À1 using a rotary vein pump and a calibrated flow meter. The quercetin SLM sample was weighed (1 mg ± 0.05 mg) into a size 3 gelatine capsules, which was then insert into an Aerolizer Ò device and the pump activated for 4 s to disperse the powder. The TSI was then disassembled and the Transwel l removed. After deposition of the powder, the Transwell was placed into a 24 well plate containing 300 lL modified buffer (HBSS supplem ented with HEPES (1% v/v), and ethanol 97% (1% v/ v) at pH 7.4) to measure the quercetin transport.
At 30 min time points the Transwells were moved to new well containing fresh modified buffer. After 4 h the surface of the monolayer was washed with transport buffer to account for the drug remaining on cell surface and the cells were lysed with Cell Lytic solution to allow the measure ment of the drug in the cells. The lysates were centrifuged at 10,000 rpm for 10 min at 4°C. The supernatant was collected and diluted to an appropriate volume. All the samples were analysed by HPLC. The initial amount deposited on the cell layer was calculated from the sum of the drug passed through the cell monolay er, the mass retained on the monolay er at the end of the experime nt and the mass of drug inside the cells. Experime nts were randomised for dose and repeated three times.
Statistica l analysis
Data was subjected to statistical analysis (SPSS 17.0), using AN-OVA one-way analysis to examine for significant differenc e. Significant differences between formulations were analysed using multiple comparisons (Tukeys post hoc test) and P values of <0.05 were considered to be significant.
Results
Physicochemica l characteristics of quercetin solid lipid microparticl es
For the preparation of the SLMs, tristearin and hydrogenated phosphatidy lcholine were selected respectively as lipidic material and surfactant, based on a previous study on the developmen t of quercetin-lo aded lipid micropartic les for dermal application ). In addition, phosphatidy lcholine is a physiological compatible emulsifier (phosphatidylcholine is the major component of lung endogenous surfactant). The quercetin content of the SLMs was 15.5% w/v ± 0.6, which corresponded to an encapsulation efficiency of 71.4% (encapsulation efficiency is based on the recovered amount of quercetin in the microparticles as a function of the theoretical amount present in the powder when taking into account the excipients content) .
Particle size analysis
The particle size distribut ion of the as supplied micronised quercetin and quercetin SLMs are shown in Fig. 1 with analysis of the data indicating median volume diameters (d 0.5 ) of 2.28 ± 0.03 lm and 2.90 ± 0.30 lm, respectively. Further analysis suggested 90% of the SLMs had a diameter 611.08 ± 1.09 lm.
Scanning electron microscopy
Scanning electron microscop y images of the SLMs and as-supplied quercetin are shown in Fig. 2A and B , respectivel y. In general the SLMs particles had a spherical morphology and a size in line with particle size analysis, while raw quercetin was columnar in shape and larger than 10 lm. It is important to note that particle size data is represented as volume distribution and makes a series of assumptions (i.e. uniform spheres), while SEM is a 'morphological' techniqu e. This is reflected by the differences observed in particle size when compared with SEM images, where particles appear to have an elongated or plate-like morphology. Particle size distribution for the SLMs was of an appropriate size for respiratory delivery (Patton, 1999 ) and similar to that measured using laser diffraction.
Differential scanning calorimet ry
The thermal response of the SLM components; tristearin, phosphatidylchol ine and quercetin, as well as the prepared SLMs are displayed in Fig. 3 . Tristearin is a commercial monoacid triglyceride. Generally, triglycerides exhibit three different polymorphic forms characterised by particular chain packing and thermal stability: alpha (a), beta-prime (b 0 ), and beta (b) (Hernqvist, 1990 ) . In this specific experiment, tristearin presented an endotherm corresponding to the melting of the b phase at 63.75 °C, similar to previous literature (Lutton, 1945 ) . Phosphati dylcholine is a surface-active molecule. Its transition temperat ure from crystalline to mesomo rphic (liquid crystalline) was visible at around 84.22 °C, in agreement with previously reported values (Rutven and McElhaney, 2011 ) .
The DSC thermogram of quercetin raw material exhibited an endothermi c peak at 321 °C, typical of melting, in line with literature data (Borghetti et al., 2009 ) . Another smaller endothermic peak is visible at around 137 °C related to a decompo sition process with water loss (Da Costa et al., 2002 ) .
The DSC thermogram of the prepared SLMs showed a noticeable reduction in the melting point in comparis on with quercetin raw material, followed by an endothermi c response. These results are supported by various previous studies conducted on the phospholipid complexes of some phytoconsti tuents such as silybin, puerarin curcumin, naringenin and gallic acid (Maiti et al., 2007; Semalty et al., 2010 ) . It is hypothes ised that the main exothermic event is due to the melting of the primary excipient, tristearin and the simultaneou s dissolution of the drug and phospholipid in the melt. The significance of the DSC data is that the quercetin appears incorporate d into the matrix; an essential requiremen t with respect to stability and release profile modification.
X-ray powder diffraction
The diffractogra m of raw quercetin and quercetin SLMs measured using XRPD is shown in Fig. 4 . The XRPD pattern of the starting material indicated a highly crystalline structure, as evident from the sharp peaks observed at 14, 16, and 27 of 2h values. This was in good agreement with a previous study of quercetin (Sri et al., 2007 ) . In comparison, the SLMs had no characteristic peaks of a crystalline structure suggesting the particles to be amorphous. The incorporati on of the drug into the lipid matrix is likely to enhance stability of the drug and control release after deposition. This is reflected in the DVS and in vitro experiments presented in Sections 3.1.5 and 3.4 , respectievely .
Dynamic Vapour Sorption
Dry powder inhalers are inherentl y susceptible to moisture sorption and thus elevated relative humidity (RH). To further study the SLMs, the powders were exposed to two 0-90% RH cycles using a DVS. Time vs. mass plots as a function of humidity are shown in Fig. 5A while the moisture sorption isotherm for the first humidity ramp (cycle 1) is shown in Fig. 5B . In general, all of the formulat ion components were reversible in terms of moisture sorption/des orption suggesting no irreversible polymorphic change or crystalisation phenomena . The moisture sorption was highest for phosphat idylcholine (14.5% at 90% RH) compare d with 0.8% and 0.1% for quercetin and tristearin, respectively. The moisture sorption of the SLMs was 3.3% at 90% RH. The reduction in moisture sorption for the SLMs in comparison to the phosphatidy lcholine (which equates for $13% of the SLM particle mass) is most likely due to the contributing effects of the drug and tristearin (which make up the majority of the particle) and the presence of phosphatidylchol ine on the surface of the particles (contributing to the high humidity sorption of SLMs).
In vitro aerosolisation studies
The aerosolisation performanc e of quercetin SLMs was studied using the NGI and the data is presented in Fig. 6 . Analysis of the stage deposition data, capsule and device recovery indicated that 96.87% ± 1.51% of the loaded dose was recovered across all stages (indicating good mass balance). In addition, the fine particle dose (FPD) and fine particle fraction (FPF) were calculated to be 316.2 ± 52.3 lg and 20.5 ± 3.3%. The FPD and FPF represented the dose and percentage drug concentratio ns with an aerodynamic diameter less than 4.46 lm, suitable for inhalatio n delivery.
Cell viability assay
The dose response cytotoxicity profile of quercetin SLMs on Calu-3 cells was established and is shown in Fig. 7 . Calu-3 cell cultures were exposed to a range of SLMs concentratio ns (from a minimum of 0.15 nM to a maximum of 200,000 nM) over a 72 h treatment period. Cells viability was calculated with reference to the untreated cells, where average absorbance was normalised to 100% viability. The viability assay demonst rated that Calu-3 cells Fig. 4 . The X-ray powder diffractogram of raw quercetin and quercetin SLMs. could tolerate a wide range of quercetin concentrations . The IC50 value could not be determined across the concentratio n range and thus, the SLMs should be considered non-toxic for Calu-3 cells.
TEER of the Calu-3 monolayer was measured after 240 min of exposure to quercetin, quercetin SLMs, tristearin and phosphat idylcholine. This was performed to determine if any of the components in the formulation could change the integrity of the epithelial cells. It was found that there was no significant difference (P > 0.05) between the control cells and cells treated with quercetin (550 ± 40 X cm 2 ), quercetin SLMs (550 ± 30 X cm 2 ), tristearin (580 ± 30 X cm 2 ), phosphatidy lcholine (600 ± 55 X cm 2 ) or co-depositio n of tristearin and phosphatidylch oline (560 ± 23 X cm 2 ).
Although to the authors' knowledge, no previous viability studies have used Calu-3 epithelial cells, flavonoids are ubiquitous in the human diet, are highly bioavailable, and have been extensive ly studied with regard to their pharmacology and toxicology (Rossand and Kasum, 2002 ) .
Furthermor e, multiple laboratory clinical trials point to an excellent safety profile of quercetin, including studies using systemic, oral, and intravenous administrat ion (Hard et al., 2007 ) . Consequentl y in this study it could safely be assumed that quercetin SLMs are not toxic for the concentr ations studied.
3.4. In vitro drug diffusion/tra nsport studies using an air interface Calu-3 cell culture
The percentage of drug transported through the Calu-3 cell grown on the Transwel l in the AIC configuration and attached to the modified TSI apparatu s is shown in Fig. 8 . Drug concentr ations were measured and expresse d in terms of percent total recovery througho ut the experiments and data was plotted as mean cumulative percentage (±standard deviation ) of drug transport over 4 h. Data analysis demonstrat es a linear kinetic profile, with a maximum of 22.32 ± 1.51% drug transported after 4 h from SLM formulation. Importan tly, quercetin was not detectable in the basal chamber 4 h after deposition of the micronised quercetin micro particles . Such observations suggest that the rate-limiting step in uptake of quercetin SLMs was linked to the solubility, presumably due to the amorphous nature of quercetin trapped within the solid lipid matrix, since the flux is independen t of quercetin concentration remaining on the cell monolayer.
After deposition of SLMs on the Calu-3 cells grown in the AIC model, the concentratio n of quercetin transported into the basal Fig. 6 . Quercetin SLMs aerosol deposition by next generation impaction. S1-S8 represents NGI stages cut off diameters: S1 > 8.06; S2 > 4.46; S3 > 2.82; S4 > 1.66; S5 > 0.94; S6 > 0.55; S7 > 0.34; S8 > 0.34 lm, respectively. compartme nt at set time points was measured and the cumulati ve mass and percentage transport calculated. Fig. 9 depicts the percentage of drug transported, remaining on the cells and trapped within the cells, from the single quercetin and quercetin SLMs.
After 240 min 45.26 ± 7.23% of quercetin SLMs and >86.79 ± 1.96% of quercetin alone was still found to be on the cells surface, while 31.25 ± 7.40% and 13.20 ± 1.96% (from SLM formulation and quercetin alone, respectively ) was found 'trapped' inside the cells. Only 22.32 ± 1.51% of drug from the SLM formulation was transported across the Calu-3 and was found in the basal compartment. No quercetin raw material was transported to the basal compartme nt.
Discussion
Phosphatidylchol ine has previously been shown to have skin penetration enhancing characterist ics in other studies (Saija et al., 1998 ) . Specifically, a previous study has also shown that didecanoyl-L-alpha-p hosphatidylchol ine enhances the nasal absorption of insulin, in an in vitro rabbit nasal mucosa model, by facilitating a paracellul ar passage through a reversible opening of tight junctions (Carstens et al., 1993 ) . Here we studied the deposition and transport of both quercetin SLM and micronis ed quercetin, alone. The quantities deposited were different between the SLM (0.4 lg) and micronised material (2.8 lg) since we attempted to achieve equivalent deposited masses of powder at the epithelia (i.e. including the lipid components ). In addition, the higher mass of micronised sample was additionally tested to study if micronised material would be transported at all.
Only quercetin from SLM produced any epithelial transport across the cell line (although some internalizat ion of quercetin was observed for the micronized samples). The enhancement effect achieved by the lipid micropartic les could be traced to a more effective delivery of quercetin to the cells due to increased contact surface between the encapsul ated substance and the cells. In addition, since the lipid microparticles enable slow release of quercetin at the cell surface over time, the extent of decompo sition/oxidativ e degradation is reduced compared to the free drug, which is immediately available.
Lipid carrier with incorporated drugs has been demonstrat ed to increase the absorption and circulation in the body versus standalone compound s (Maeda, 2001 ) . For nontoxic enhancer s that have proven successful in in vivo studies, additional mechanis ms to paracellular enhancement have been suggested (Gizurarson and Bechgaard, 1991 ) . For instance, increased cell membrane permeability caused by enhancer incorporation into the luminal cell membrane has been suggested (Muranishi, 1990 ) , but how this could induce drug transcellular absorption is unclear.
Although this study indicates that the absorption of quercetin is enhanced by the presence of phosphat idylcholine or tristearin, the real mechanism is still unclear. It is possible that the phospholipid may be incorporated into the luminal cell membrane, and this may constitute the primary step in the mechanism by which phosphatidylcholine affects tight junction permeability. Furthermore, changes in the lipid environm ent of the cell membrane may affect the basic transport properties of the Calu-3 epithelium. Additional studies are needed to evaluate this possibility.
Conclusion s
This study has investigated the formulation and aerosol delivery to the lung of solid lipid quercetin microparticles as a potential active pharmaceuti cal ingredient for asthma therapy. We have demonstrat ed SLM particle technology can be used to deliver this naturally derived flavonoid for the treatment of range of respira-tory diseases. The effect of the absorption enhancing non-toxic excipients in increasing the permeabilit y of quercetin has also been highlight ed; making this approach significant, since the raw micronis ed quercetin was not transported across epithelia. To the authors knowled ge no previous studies have investigated quercetin transport mechanis m using Calu-3 cell epithelial monolayer. This is an important aspect of the study since the lung epithelia will be the first barrier after deposition in the airways. Further studies are necessary to elucidate the exact mechanism.
Due to the natural physiologica l composition of the quercetin and its components in the final SLMs, this system has the potential to be used as a 'bio-comp atible' delivery system to modulate the release of inhaled dry powder formulat ions.
